Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(13 sites)
France
Hôpital Avicenne, Bobigny CHU Henri Mondor, Créteil Centre Hospitalier Lyon Sud, Lyon, Lyon Hôpital de la Conception, AP-HM, Marseille AP-HP Hôpital Saint Louis, Paris AP-HP Hôpital Cochin, Paris Centre Henri Becquerel, Rouen Gustave Roussy, Villejuif